Item 8.01. Other Events.
On September 18, 2020, Seattle Genetics, Inc. and Astellas Pharma Inc. issued a
press release announcing top-line results from the global, phase 3 EV-301
clinical trial, which compared PADCEV® (enfortumab vedotin-ejfv) to chemotherapy
in adult patients with locally advanced or metastatic urothelial cancer who were
previously treated with platinum-based chemotherapy and a PD-1/L1 inhibitor. A
description of these top-line results is contained in the press release dated
September 18, 2020, which is attached as Exhibit 99.1 to this current report and
is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 Press Release of Seattle Genetics, Inc. and Astellas Pharma Inc. dated
September 18, 2020
104 Cover Page Interactive Data File (formatted as Inline XBRL)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
SEAGEN INC. 
